Does clomiphene in early pregnancy increase the risk of hypospadias?
Evidently not, according to a large, Danish, population-based, case–control study.
Evidently not, according to a large, Danish, population-based, case–control study.
Clomiphene, which is structurally related to diethylstilbestrol (DES), has been linked to urogenital anomalies and testicular cancer in males exposed in utero. In addition, hypospadias has been reported in boys born to women exposed to DES in utero.
But this latest study calculated an odds ratio of developing hypospadias after exposure to clomiphene of only 0.48 (95% CI; 0.15–1.54). Restricting exposure to clomiphene to the first trimester and up to 30 days prior to conception did not alter the result substantially.
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
